Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

Other equities analysts also recently issued research reports about the stock. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price objective (down previously from $9.00) on shares of Kamada in a research note on Wednesday, August 2nd. TheStreet downgraded shares of Kamada from a “c-” rating to a “d+” rating in a research note on Tuesday, August 1st. Finally, ValuEngine downgraded shares of Kamada from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $8.50.

Kamada (KMDA) remained flat at $4.75 during mid-day trading on Wednesday. The company had a trading volume of 20,711 shares. Kamada has a 1-year low of $3.75 and a 1-year high of $8.61. The company’s 50-day moving average is $4.57 and its 200 day moving average is $6.03. The company’s market cap is $177.65 million.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $32.55 million during the quarter, compared to the consensus estimate of $33.30 million. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. Kamada’s revenue for the quarter was up 70.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. On average, analysts expect that Kamada will post $0.09 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Kamada Ltd. (KMDA) Downgraded by Zacks Investment Research to “Sell”” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/04/kamada-ltd-kmda-downgraded-by-zacks-investment-research-to-sell.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Edmond DE Rothschild Holding S.A. grew its holdings in Kamada by 10.5% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,000 shares during the last quarter. Navellier & Associates Inc purchased a new stake in shares of Kamada during the second quarter valued at $303,000. Renaissance Technologies LLC grew its holdings in shares of Kamada by 16.7% during the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after buying an additional 37,800 shares during the last quarter. Nexthera Capital LP purchased a new stake in shares of Kamada during the second quarter valued at $1,805,000. Finally, Vanguard Group Inc. grew its holdings in shares of Kamada by 6.5% during the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after buying an additional 28,382 shares during the last quarter. 7.29% of the stock is currently owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.